Cost effectiveness of rituximab for non-hodgkins lymphoma: A systematic review

被引：7

作者：

Auweiler P.W.P. ^{[1
]}

Mller D. ^{[1
]}

Stock S. ^{[1
]}

Gerber A. ^{[2
]}

机构：

[1] Institute for Health Economics and Clinical Epidemiology, University Hospital of Cologne (AR), 50931 Cologne

[2] Institute for Quality and Efficiency in Health Care, Cologne

来源：

PharmacoEconomics | 2012年 / 30卷 / 7期

关键词：

Antineoplastics; Cost-effectiveness; Cost-utility; Diffuse-large-B-cell-; lymphoma; Follicular-lymphoma; Non-Hodgkins-lymphoma; Rituximab;

D O I：

10.2165/11591160-000000000-00000

中图分类号：

学科分类号：

摘要：

The monoclonal antibody rituximab has shown clinical effectiveness in combination with chemotherapy for the treatment of non-Hodgkin's lymphoma (NHL) in several randomized controlled studies. Rituximab maintenance therapy is associated with significant improvement in progressionfree and overall survival in patients with NHL. However, treatment with rituximab causes considerable costs for healthcare systems. Objective: This article provides an overview of economic evaluations of rituximab and appraises their methodological quality. Methods: A systematic literature search of cost-effectiveness studies on rituximab was carried out in nine electronic databases: MEDLINE, EMBASE, Cochrane Database of Systematic Reviews (CDSR), the German Agency of Health Technology Assessment (DAHTA) database, German Institute for Quality Improvement (DIQ)-Literatur,DIQ-Projekte, Database of Abstracts ofReviews of Effects (DARE), Health Technology Assessments (HTA) database and Sozialmedizin (SOMED) [languages: English, German, Dutch, French, Spanish and Italian; publication period: 1998 to 2010]. Based on pre-specified inclusion criteria, costeffectiveness studies were identified that compared standard chemotherapy with standard chemotherapy plus rituximab in patients with a subtype of NHL. The methodological quality of the studies was assessed using a quality checklist. Results: Fourteen economic evaluations from seven different countries were included in the review. All economic evaluations reported incremental costeffectiveness ratios (ICERs) for the add-on therapy with rituximab that were below the country-specific thresholds. The studies differed significantly in their characteristics and methodological rigour. Most studies lacked transparency regarding identification and justification of data. In several studies, the rationale for the model structure was not described appropriately. Conclusion: Adding rituximab to standard chemotherapy is considered a costeffective treatment option for NHL. However, the results of the analyses should be interpreted with caution due to methodological limitations. Adis © 2012 Springer International Publishing AG.

引用

页码：537 / 549

页数：12

共 44 条

[1]

Fisher S.G., Fisher R.I., The epidemiology of non-Hodgkin's lymphoma, Oncogene, 23, 38, pp. 6524-6534, (2004)

[2]

Coltman C., Dahlberg S., Jones S., CHOP is curative in thirty percent of patients with large cell lymphoma

[3]

A twelve-year Southwest oncology group follow-up, Advances in Cancer Chemotherapy, (1986)

[4]

Messori A., Vaiani M., Trippoli S., Rigacci L., Jerkeman M., Longo G., Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: Meta-analysis of randomized studies comparing third generation regimens with CHOP, British Journal of Cancer, 84, 3, pp. 303-307, (2001)

[5]

Van Oers M.H.J., Klasa R., Marcus R.E., Wolf M., Kimby E., Gascoyne R.D., Jack A., Van't Veer M., Vranovsky A., Holte H., Van Glabbeke M., Teodorovic I., Rozewicz C., Hagenbeek A., Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial, Blood, 108, 10, pp. 3295-3301, (2006)

[6]

Czuczman M.S., Grillo-Lopez A.J., White C.A., Saleh M., Gordon L., LoBuglio A.F., Jonas C., Klippenstein D., Dallaire B., Varns C., Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, Journal of Clinical Oncology, 17, 1, pp. 268-276, (1999)

[7]

Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C., Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma, New England Journal of Medicine, 346, 4, pp. 235-242, (2002)

[8]

Marcus R., Imrie K., Belch A., Cunningham D., Flores E., Catalano J., Solal-Celigny P., Offner F., Walewski J., Raposo J., Jack A., Smith P., CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, 105, 4, pp. 1417-1423, (2005)

[9]

Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., Reiser M., Metzner B., Harder H., Hegewisch-Becker S., Fischer T., Kropff M., Reis H.-E., Freund M., Wormann B., Fuchs R., Planker M., Schimke J., Eimermacher H., Trumper L., Aldaoud A., Parwaresch R., Unterhalt M., Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular l

[10]

Pfreundschuh M., Trumper L., Osterborg A., Et al., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group, Lancet Oncol, 7, pp. 379-391, (2006)

← 1 2 3 4 5 →